ANTX vs AVIR
ANTX: AN2 Therapeutics leverages a proprietary boron chemistry platform to develop small-molecule drugs for neglected infectious diseases, blood cancers, and other high-unmet-need conditions. AVIR: A clinical-stage antiviral company advancing pan-genotypic HCV and HEV therapies toward FDA submissions, leveraging proprietary nucleoside/nucleotide chemistry for differentiated viral treatment regimens.
Side-by-side fundamentals
| Metric | ANTX | AVIR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.89 | $4.81 | |
| Market cap as of 2026-07-23 | $176M | $385M | |
| PEG as of 2026-07-23 | n/a | -0.08 | |
| Net margin as of 2026-07-23 | n/a | +34.5% | |
| Operating margin as of 2026-07-23 | n/a | +39.4% | |
| ROE as of 2026-07-23 | -52.3% | -57.0% | ANTX higher |
| ROA as of 2026-07-23 | -47.3% | -51.5% | ANTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | -1.00 | 0.27 | |
| 1-year return as of 2026-07-22 close | +342.5% | +42.0% | ANTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.